INAB
IN8BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.08
+0.93%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.05
From 52W high−58.30%
Volume20301.00
Market cap$10.65M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.05
From 52W high
−58.30%
Volume
20301.00
Market cap
$10.65M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
46.4
MomentumView details →
1D Return
+0.93%
YTD Return
−54.27%
SummaryUpdated Jun 1, 2026
IN8bio, Inc. (NASDAQ:INAB) is a clinical-stage biotechnology company founded in 2016 and headquartered in New York, New York. Originally incorporated as Incysus Therapeutics, Inc., the company changed its name to IN8bio in August 2020 and went public in July 2021. The company specializes in developing innovative cancer treatments using gamma-delta T cell therapies, representing a cutting-edge approach in the field of cellular immunotherapy for oncology applications.
Similar companies
Latest newsMore news →
IN8bio hired Oxana Polyakova as senior vice president of research & development; she previously served as chief scientific officer at LAVA Therapeutics.2d agoIN8BIO, Inc. terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, effective May 29, 2026.112d agoIN8BIO, Inc. entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC to sell common stock from time to time in an at-the-market offering.112d ago